Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Taysha Gene Therapies (TSHA) Shares Issued (2022 - 2025)

Taysha Gene Therapies' Shares Issued history spans 4 years, with the latest figure at $122000.0 for Q3 2025.

  • For Q3 2025, Shares Issued rose 93.65% year-over-year to $122000.0; the TTM value through Sep 2025 reached $197000.0, down 63.45%, while the annual FY2024 figure was $89000.0, 82.2% down from the prior year.
  • Shares Issued for Q3 2025 was $122000.0 at Taysha Gene Therapies, up from $75000.0 in the prior quarter.
  • Across five years, Shares Issued topped out at $432000.0 in Q4 2023 and bottomed at -$11.4 million in Q3 2022.
  • The 4-year median for Shares Issued is $56500.0 (2023), against an average of -$1.0 million.
  • The largest annual shift saw Shares Issued plummeted 81.95% in 2023 before it surged 250.0% in 2024.
  • A 4-year view of Shares Issued shows it stood at -$11.4 million in 2022, then soared by 103.79% to $432000.0 in 2023, then tumbled by 85.42% to $63000.0 in 2024, then surged by 93.65% to $122000.0 in 2025.
  • Per Business Quant, the three most recent readings for TSHA's Shares Issued are $122000.0 (Q3 2025), $75000.0 (Q1 2025), and $63000.0 (Q3 2024).